Lauersen N H, Wilson K H, Fuchs F
Am J Obstet Gynecol. 1975 Mar 1;121(5):597-601. doi: 10.1016/0002-9378(75)90458-5.
Berotec (Th 1165a), a specific beta-adrenergic agent, has been found to be a more potent agent than metaproterenol in the inhibition of uterine activity in animals and human beings. The effect of berotec on spontaneous (postinduced) and induced uterine activity in the pregnant baboon near term was investigated. Berotec administered intravenously in a dose of 5 mug per minute consistently and significantly reduced spontaneous uterine activity as well as uterine activity by either oxytocin or prostaglandin F2-alpha. The frequency of contractions was consistently reduced whereas the effect on the amplitude of contractions was less marked. There was no reduction of the baseline muscle tonus. Berotec infusion produced a marked increase in the maternal heart rate, averaging 40 beats per minute. Berotec appears to be a potent inhibitor of spontaneous, oxytocin-induced, and prostaglandin-induced uterine activity in the pregnant baboon, but it has considerable cardiovascular side effects.
博利康尼（Th 1165a），一种特效β - 肾上腺素能制剂，已发现在抑制动物和人类子宫活动方面比间羟异丙肾上腺素更有效。研究了博利康尼对近足月妊娠狒狒的自发（诱导后）和诱导子宫活动的影响。以每分钟5微克的剂量静脉注射博利康尼，持续且显著地降低了自发子宫活动以及由催产素或前列腺素F2 - α引起的子宫活动。宫缩频率持续降低，而对宫缩幅度的影响则不太明显。基线肌肉张力没有降低。博利康尼输注使母体心率显著增加，平均每分钟增加40次。博利康尼似乎是妊娠狒狒自发、催产素诱导和前列腺素诱导子宫活动的有效抑制剂，但它有相当大的心血管副作用。
